Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Condition(s):MelanomaLast Updated:July 24, 2018Completed
Hide Studies Not Open or Pending
Condition(s):MelanomaLast Updated:July 24, 2018Completed
Condition(s):Glioblastoma; Glioma of BrainLast Updated:November 8, 2019No longer available
Condition(s):NSCLC Stage IV; HIV; HBV; HCV; Long COVIDLast Updated:October 28, 2022Not yet recruiting
Condition(s):Melanoma; Ocular MelanomaLast Updated:April 11, 2023Active, not recruiting
Condition(s):Malignant MelanomaLast Updated:December 27, 2023Active, not recruiting
Condition(s):Hepatocellular CarcinomaLast Updated:December 13, 2022Recruiting
Condition(s):Malignant MelanomaLast Updated:August 29, 2017Terminated
Condition(s):Brain MetastasesLast Updated:June 2, 2015Unknown status
Condition(s):Melanoma Stage III; Melanoma Stage IVLast Updated:March 5, 2020Completed
Condition(s):Advanced Cancers; MelanomaLast Updated:October 23, 2023Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.